Open Access

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

  • Authors:
    • Melissa Bersanelli
    • Elisabetta Lattanzi
    • Nunziata D'Abbiero
    • Sebastiano Buti
    • Alessandro Leonetti
    • Maria Giulia Canè
    • Salvatore Trapani
    • Gianluca Gravina
    • Giampiero Porzio
    • Katia Cannita
    • Pietro Di Marino
    • Antonino Grassadonia
    • Nicola Tinari
    • Michele De Tursi
    • Elisa Giaiacopi
    • Maria Michiara
    • Paola Bordi
    • Fabiana Perrone
    • Luciana Caravatta
    • Marianna Trignani
    • Domenico Genovesi
    • Clara Natoli
    • Corrado Ficorella
    • Marcello Tiseo
    • Alessio Cortellini
  • View Affiliations

  • Published online on: December 13, 2019     https://doi.org/10.3892/br.2019.1265
  • Pages: 59-67
  • Copyright: © Bersanelli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, the influence of purely palliative radiotherapy (pRT) on the outcomes of patients with advanced cancer undergoing immune checkpoint blockade was evaluated. Patients were stratified into three groups: Patients who had received pRT within 6 months prior to the initiation of immunotherapy (previous pRT); patients who received pRT during immunotherapy (concurrent pRT); and patients who did not receive RT prior to or during immunotherapy (no RT group), and these groups were compared. The median overall survival (mOS), median progression free survival (mPFS) and median time‑to‑treatment failure (mTTF) for the previous pRT group were significantly shorter compared with the no RT group (mOS, 3.6 vs. 12.1 months, respectively, P=0.0095; mPFS 1.8 vs. 5.4 months, respectively, P=0.0016; mTTF 1.8 vs. 5.7 months, respectively, P=0.0035). The concurrent pRT group had a longer mTTF compared with the previous pRT group and similar outcomes to the no RT group. In the previous pRT group, 26.9% of the patients experienced immune‑related adverse events compared with 40.1% of patients in the no RT group. Despite the use of pRT during immunotherapy being considered safe, the results of the present study suggest that pRT has a negative effect on immune balance.
View Figures
View References

Related Articles

Journal Cover

February 2020
Volume 12 Issue 2

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Bersanelli, M., Lattanzi, E., D'Abbiero, N., Buti, S., Leonetti, A., Canè, M.G. ... Cortellini, A. (2020). Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study. Biomedical Reports, 12, 59-67. https://doi.org/10.3892/br.2019.1265
MLA
Bersanelli, M., Lattanzi, E., D'Abbiero, N., Buti, S., Leonetti, A., Canè, M. G., Trapani, S., Gravina, G., Porzio, G., Cannita, K., Di Marino, P., Grassadonia, A., Tinari, N., De Tursi, M., Giaiacopi, E., Michiara, M., Bordi, P., Perrone, F., Caravatta, L., Trignani, M., Genovesi, D., Natoli, C., Ficorella, C., Tiseo, M., Cortellini, A."Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study". Biomedical Reports 12.2 (2020): 59-67.
Chicago
Bersanelli, M., Lattanzi, E., D'Abbiero, N., Buti, S., Leonetti, A., Canè, M. G., Trapani, S., Gravina, G., Porzio, G., Cannita, K., Di Marino, P., Grassadonia, A., Tinari, N., De Tursi, M., Giaiacopi, E., Michiara, M., Bordi, P., Perrone, F., Caravatta, L., Trignani, M., Genovesi, D., Natoli, C., Ficorella, C., Tiseo, M., Cortellini, A."Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study". Biomedical Reports 12, no. 2 (2020): 59-67. https://doi.org/10.3892/br.2019.1265